EcoDrugPlus

Phosphodiesterase 3b

Ensembl ID : ENSAPOG00000004290
Gene Symbol: PDE3B
3 Cross references
204 Possible Orthologues:

Phosphodiesterase 4b

Ensembl ID : ENSAPOG00000014832
Gene Symbol: PDE4B
3 Cross references
226 Possible Orthologues:

Phosphodiesterase 5a

Ensembl ID : ENSAPOG00000017195
Gene Symbol: PDE5A
3 Cross references
208 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSAPOG00000018794
Gene Symbol: PDE7A
3 Cross references
215 Possible Orthologues:

Phosphodiesterase 7b

Ensembl ID : ENSAPOG00000013020
Gene Symbol: PDE7B
3 Cross references
174 Possible Orthologues:

Phosphodiesterase 9a

Ensembl ID : ENSAPOG00000007543
Gene Symbol: PDE9A
3 Cross references
192 Possible Orthologues:

Phosphoinositide 3-Kinase Regulatory Subunit 5-Like

Ensembl ID : ENSAPOG00000002939
Gene Symbol: LOC110948923
3 Cross references
184 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSAPOG00000013196
Gene Symbol: PIK3R5
3 Cross references
202 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 2 (Beta)

Ensembl ID : ENSAPOG00000024009
Gene Symbol: PIK3R2
1 Cross references
190 Possible Orthologues:

Phospholipase A2 Group Vii

Ensembl ID : ENSAPOG00000023844
Gene Symbol: PLA2G7
3 Cross references
206 Possible Orthologues:

Phospholipase A2-Like

Ensembl ID : ENSAPOG00000003188
Gene Symbol: LOC110965396
3 Cross references
233 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSAPOG00000009958
Gene Symbol: GART
3 Cross references
214 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).